GSK3A and atherosclerosis: Results from our lab suggest that myeloid deletion of GSK3α, pharmacological mitigation of ER stress (by 4 phenylbutyrate), or inhibition of GSK3α/β (by valproate) attenuates the progression of atherosclerosis (29–32).